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Abstract
Background: Sandostatin
® LAR
® (Novartis Pharma AG) is a long-acting repeatable formulation of the somatostatin
analogue octreotide, the safety and efficacy of which has been established through 15 years of clinical experience.
Recently, other formulations of octreotide using polymer poly(lactic-co-glycolic acid) technology have been
developed. This study compares the composition and pharmacokinetic (PK) profile of Sandostatin LAR with three
other versions of the depot delivery system (formulations A, B and C, available in selected countries).
Findings: Sandostatin LAR exhibited a characteristic concentration-time profile with a limited initial release of
octreotide (’burst’), an erosion phase from weeks 3-5, and a slowly declining concentration to day 52. The PK
profiles of formulations A and B were characterized by a large initial burst during days 0-2, with up to 41% of the
overall area under the plasma-concentration time curve achieved. Low and variable octreotide concentrations were
observed during the microparticle erosion phase (days 2-62 [day 82 formulation C]) for formulations A, B and C.
Sandostatin LAR microparticles are spherical in shape with an average diameter of approximately 50 μm,
determined by scanning electron microscopy evaluation. Formulation A had smaller, irregular microparticles, and
formulations B and C exhibited a large range of particle diameters (< 20 to > 100 μm). Inductively coupled plasma-
optical emission spectroscopy detected a high tin content of 104 mg/kg in formulation B, the presence of which
may suggest inadequate purification following polymer synthesis using tin(II)-octoate as catalyst. PK profiles for
formulations A, B and C after a single intramuscular injection of 4 mg/kg in male New Zealand rabbits differed
markedly from the PK profile of Sandostatin LAR.
Conclusions: Clear differences were seen between Sandostatin LAR and formulations A, B and C, including
variations in microparticle size, shape and impurity content. Considering the significant differences in the octreotide
release profile between Sandostatin LAR and the other formulations, the safety and efficacy of the other
formulations cannot be inferred from the Sandostatin LAR efficacy and safety profile; each of these other
formulations should be assessed accordingly.
Findings
Background and aims
Sandostatin
® LAR
® is a long-acting octreotide formula-
tion for the treatment of patients with acromegaly and
symptoms associated with certain types of neuroendo-
crine tumors. Approved at doses of 10, 20 and 30 mg
(and up to 40 mg for patients with acromegaly in cer-
tain countries such as the US and Japan), Sandostatin
LAR allows for once-monthly administration,
maintaining the efficacy of Sandostatin immediate-
release whilst significantly reducing the number of injec-
tions administered [1,2]. Based on a well defined and
consistent pharmacokinetic (PK) profile, the efficacy and
safety of Sandostatin LAR have been established over
more than a decade of clinical experience [3].
Recently, other long-acting octreotide formulations
have become available for clinical use in selected mar-
kets. Evidence regarding bioequivalence or product
property equivalence between these new formulations
and Sandostatin LAR is not available. Such information
is important as clinical guidelines recommending the * Correspondence: holger.petersen@novartis.com
Novartis Pharma AG, Basel, Switzerland
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ence with Sandostatin LAR, and assumes that other
long-acting octreotide formulations would be of a simi-
lar quality, uniformity and reliability. Here we report
findings from a series of assessments performed to com-
pare Sandostatin LAR with three other formulations of
long-acting octreotide manufactured by companies other
than Novartis.
The properties of Sandostatin
® LAR
®,a n dt h o s eo f
three other long-acting octreotide products, were quan-
titatively and qualitatively assessed. Formulations A, B
and C were manufactured from 2008-2009. The evalua-
tions aimed to compare the composition and physico-
chemical properties of the other formulations with those
of Sandostatin LAR. PK data were compared using a
rabbit model. The different formulations were tested in
three separate animal studies of similar study design
that allowed for comparison of data.
Methods
Microparticle appearance and composition
Samples were analyzed according to cGLP in an
unblinded manner. Scanning electron microscopy
(Zeiss Supra 40) was used to evaluate microparticle
size, shape, porosity and surface appearance. Samples
were sputtered with gold-palladium prior to analysis.
For evaluation of cross-sections, microparticles were
embedded in an epoxy resin, polymerized and frac-
tured in liquid nitrogen before sputtering with gold-
palladium. Proton nuclear magnetic resonance (
1H-
NMR) was used to assess the composition of each for-
mulation and to determine the ratio of lactide to gly-
colide within the poly(lactic-co-glycolic acid; PLGA)
polymer. Samples of 1.1-1.3 mg dissolved in 0.5 mL
dimethyl-d6 sulfoxide (DMSO-d6)w e r ea n a l y z e dw i t h
500-600 MHz
1H-NMR for 12 hours at ambient tem-
perature. Gel-permeation chromatography with IR
detection was used to determine the molecular weight
of the PLGA polymer against polystyrene standards.
Inductively coupled plasma-optical emission spectro-
scopy (ICP-OES; limit of detection 1 mg/kg) was used
to detect tin levels in the polymer by measuring any
residual presence of the tin(II)-octoate catalyst. The
sample was decomposed at 250°C in a closed pressur-
ized system and signals were quantified versus an
external calibration function.
Analysis of PK parameters
Sandostatin LAR, as well as formulations A, B and C,
were administered as single intramuscular injections at a
nominal dose of 4 mg/kg to male New Zealand white
rabbits aged 3.5-4 months and weighing 3.00-3.46 kg
(four cohorts, n = 3, 4 or 7 rabbits per group). For for-
mulations A and B, the absolute octreotide content in
the vials supplied was stated by the manufacturer to be
20 mg. As such, concentrations were calculated assum-
ing 20 mg of octreotide per vial; verification of the
octreotide content was not performed. For formulation
C, rabbits were given a target dose of 10 mg/rabbit.
Actual doses are reported in Table 1. Rabbits were
housed in single cages with elevated sitting boards, and
allowed free access to standard rabbit and guinea pig
chow and water. Environmental conditions were 19 ± 2°
C with 55 ± 15% humidity.
Blood collection was taken pre-dose, and then up to
52, 62 or 82 days post-dose. Plasma concentrations of
octreotide were determined by radioimmunoassay with a
lower limit of quantification of 0.05 ng/mL. Area under
t h ep l a s m ac o n c e n t r a t i o n - time curve (AUC), maximum
plasma concentration (Cmax) and time to Cmax (tmax)
were evaluated. Cmax and tmax values were calculated in
both the burst phase from days 0-2 (Cmax-burst;t max-burst)
and erosion phase from days 2-last sampling time (Cmax-
erosion;t max-erosion).
Animal research was performed in accordance with
international guidelines and follows the Swiss law for
animal experimentation.
Statistical methods
All PK parameters were calculated with WinNonlin soft-
ware version 5. PK parameters were calculated using a
non-compartmental model. AUC from days 0 to the last
sampling time (AUClast,i . e .A U C 0-52d,A U C 0-62d and
AUC0-82d) was calculated using the linear trapezoidal
rule. Percentage of burst from days 0-2 (AUC0-2d)w a s
calculated as: 100 × AUC0-2d/AUClast. One-way analysis
of AUC and Cmax was performed using the Kruskal-
Wallis method when data were non-parametric.
Results
Microparticle size, shape, porosity and surface
appearance
Sandostatin
® LAR
® microparticles were spherical in
shape with approximately 50 μm diameter on average
(Figure 1; Overview). In contrast, formulation A micro-
particles had a much smaller diameter and were of irre-
gular shape. The microparticles in formulations B and C
were mostly spherical in shape and had a similar mean
diameter to the Sandostatin LAR microparticles, how-
ever, a larger range of particle diameters was observed
(< 20 to > 100 μm). Furthermore, some microparticles
in formulation C had an irregular shape and appeared
to be damaged (Figure 1; Overview). Sample cross-sec-
tions of the microparticles revealed that the Sandostatin
LAR microparticles were very compact with only minor
pores, microparticles in formulation A had no pores and
those in formulation B had a very high porosity
(approximately 1-3 μm diameters: Figure 1; Cross-
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tion C available for a cross-sectional analysis.
Sandostatin LAR and formulations A, B and C incor-
porate mannitol as a bulk excipient. NMR evaluation
confirmed the presence of mannitol (Figure 2). Inspec-
tion of the microparticle surface of lyophilized samples
revealed differences in the mannitol appearance among
the formulations. Mannitol was found in a crystalline
s h a p el o o s e l yc o n n e c t e dt ot h em i c r o p a r t i c l e si nt h e
Sandostatin LAR formulation. In contrast, mannitol
typically had a non-crystalline shape in formulations A
and B. The mannitol in formulation A was also more
porous and of a smaller size than that in Sandostatin
LAR. In formulation C, mannitol particles were very
large and irregularly shaped (Figure 1; Surface).
Molecular composition
The prescribing information for Sandostatin LAR, and
formulations A and C, lists acetate as the octreotide salt;
the salt type was not stated in the prescribing
Table 1 PK parameters of Sandostatin
® LAR
®, and formulations A, B and C
PK parameters Sandostatin
® LAR
® Formulation A Formulation B Formulation C
Number of rabbits 7 4 3 3
Actual dose, mg/kg (± SD) 3.34 ± 0.236 3.42 ± 0.410 3.00 ± 1.84 1.27 ± 0.426
Burst phase, days 0-2
tmax-burst, hours, median 2 1.0 0.5 0.02
Cmax-burst, ng/mL, mean (± SD) 3.49 ± 4.21 167 ± 31.1
† 22.8 ± 18.0 20.5 ± 6.64
Erosion phase, days 2-62*
tmax-erosion, days, median 20 14 and 34 20.0 12
Cmax-erosion, ng/mL, mean (± SD) 9.97 ± 4.21 3.89 ± 1.73, and 2.42 ± 2.11 4.83 ± 3.91 13.3 ± 3.52
AUC0-last, d·ng/mL (± SD)* 179 ± 62.0 163 ± 33.7 86.1 ± 73.2 247 ± 33.4
AUC0-2d, d·ng/mL (± SD) 4.42 ± 5.70 65.3 ± 4.57 2.61 ± 0.680 2.39 ± 0.592
Burst, % (± SD) 2.19 ± 1.97 41.0 ± 6.32 22.2 ± 35.0 1
*The AUC0-last was measured over 52 days (AUC0-52d) for Sandostatin LAR, over 62 days (AUC0-62d) for formulations A and B, and over 82 days (AUC0-82d) for
formulation C.
†Cmax-burst of formulation A is significantly different to that of Sandostatin LAR.
AUC, area under the plasma concentration-time curve; Cmax, maximum plasma concentration; SD, standard deviation; tmax, time to Cmax.
Figure 1 Scanning electron microscopy comparisons of Sandostatin
® LAR
®, and formulations A, B and C.
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Figure 2
1H-NMR of Sandostatin
® LAR
®, formulation A and formulation B.Upper spectrum: Sandostatin LAR, molar ratio actide 55, glycolide 45.
Middle spectrum: formulation A, molar ratio lactide 73, glycolide 27. Lower spectrum: formulation B, molar ratio lactide 50, glycolide 50. Signals at 5.2
ppm indicate the single methine proton of the lactide monomer. Signals at 4.8 ppm are assigned to the two methylene protons of the glycolide
monomer. Signals at lower shifts than 4.5 ppm indicate mannitol (mannitol-OH and -CH/CH2).
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1H-NMR analysis of for-
mulations A and B suggested the presence of an acetate
component. Compared with Sandostatin LAR, formula-
tions A and B exhibited a lower molar ratio between the
acid and base of the octreotide salt (16% and 75% of
that ratio determined for Sandostatin LAR [100%],
respectively).
1H-NMR analysis was not performed on
formulation C due to an insufficient quantity of sample.
Molecular weight of the polymer
Differences were observed between the molecular weight
and composition of the polymer used in Sandostatin
LAR, and formulations A, B and C. Whereas the mole-
cular weight of the Sandostatin LAR polymer was 52
kDa, formulations A, B and C had lower molecular
weights of approximately 16, 32 and 14.5 kDa, respec-
tively. The ratio of the lactide:glycolide co-monomers
was 55:45 in Sandostatin LAR, 73:27 for formulation A
and 50:50 for formulation B. For formulation C, the
supplier claimed a ratio of 62.5:37.5 based on a 1:1
blend of 50:50 and 75:25 PLGA polymers.
Impurities
No heavy metals or other potentially toxic substances
were detected in Sandostatin LAR, or in formulation A.
A high tin content of 104 mg/kg was found in
formulation B. ICP-OES analysis was not performed on
formulation C due to an insufficient quantity of sample.
Comparison of PK profile in rabbits
Sandostatin LAR demonstrated controlled release of
octreotide. During the burst phase (days 0-2) the mean
Cmax-burst value was 3.49 ng/mL, corresponding to 1.9%
of the overall AUC0-52d. The octreotide concentration
increased during the erosion phase to reach mean peak
levels of 9.97 ng/mL (Figure 3; Table 1). The release pat-
tern of Sandostatin LAR demonstrated an erosion phase
in octreotide concentrations during weeks 3-5, similar to
the concentration-time profile observed in humans [4].
Compared with the PK profile of Sandostatin LAR, for-
mulations A, B and C achieved a much higher octreotide
concentration over the first 2 days post injection, display-
ing mean Cmax-burst of 167, 22.8 and 20.5 ng/mL, respec-
tively. Although Cmax-burst was high for formulation C,
AUC0-2d was relatively low. During the first 2 days after
injection, 41.0% and 22.2% of the overall AUC0-62d was
observed with formulations A and B, respectively. Conse-
quently, during the erosion phase, octreotide concentra-
tions in these formulations were much lower and more
variable compared with those of Sandostatin LAR; these
formulations had no obvious plateau phase (Figure 3).
Overall octreotide concentrations were also found to be
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Figure 3 Plasma concentration-time profiles ± SD of Sandostatin
® LAR
®, and formulations A, B and C.
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tin LAR samples demonstrated an AUC0-52d of 179 d·ng/
mL, formulation A and B demonstrated AUC0-62d of 163
and 86.1 d·ng/mL, respectively, and formulation C
demonstrated AUC0-82d of 247 d·ng/mL. Additionally,
formulation B was found to be very difficult to inject due
to needle clogging and, as a result, one rabbit was
excluded as no octreotide concentration was detected
after an unsuccessful injection. A second rabbit had an
octreotide concentration considerably lower than the
mean dose exhibited in the other cohorts (23.2% of the
intended dose, individual data not shown). Concerning
formulation C, early erosion was observed with tmax-ero-
sion of 12 days with a high Cmax-burst of 20.5 ng/mL.
Discussion
Sandostatin
® LAR
® is a long-acting repeatable formula-
tion of octreotide. Its development required extensive
analytical support to ensure the quality and consistency
of the formulation. Clinical PK studies have established
that Sandostatin LAR produces a reliable, sustained
release of octreotide [4,5], with proven therapeutic uti-
lity in patients [3,6,7]. More recently, other long-acting
formulations of octreotide have been introduced in
selected markets.
In humans, Sandostatin LAR has a well-character-
ized consistent and predictable PK profile, which can
be described as exhibiting three distinct phases: (1)
release of surface-absorbed octreotide (burst); (2) pore
diffusion, biodegradation, osmotic swelling and ionic
interactions (erosion phase leading to a drug concen-
tration plateau); and (3) fragmentation and complete
biodegradation of the polymer (erosion phase leading
to complete drug release) [8]. This tripartite pattern
has been regularly observed and is evident with var-
ious Sandostatin LAR doses. Octreotide concentra-
tions exhibited an initial peak on day 1, followed by a
decline over the following 3-5 days, before slowly
increasing and reaching a plateau 2-3 weeks post
injection before declining [4]. The steady-state PK
simulation of Sandostatin LAR 20 mg suggested a
mean concentration of 1216 pg/mL (range, 1065-1585
pg/mL) with a fluctuation index of 43%. Additionally,
inter-subject variability in mean Cmax was 32% for
Sandostatin LAR 20 mg [4].
During the in vivo rabbit PK evaluations in the present
study, differences in the concentration-time profile
between formulations A, B and C, and Sandostatin LAR,
were observed. The Sandostatin LAR concentration-time
profiles in these in vivo investigations were similar to
those observed in humans [4]. During the burst phase,
the three other formulations displayed AUC0-2d values
ranging from 2.39-65.3 d·ng/mL, compared with 4.42
d·ng/mL for Sandostatin LAR. This variability may result
from the appearance of the microparticles, and poses
potential safety risks. This finding was particularly evi-
dent in formulation A, with 41% of the overall AUC
achieved within the first 2 days after injection. Formula-
tions A and B also demonstrated much lower concentra-
tions of octreotide, while formulation C was
characterized by an early and narrow erosion phase with
no discernable plateau. As such, in addition to potential
safety concerns related to the large burst phase, the for-
mulations may also fail to consistently deliver therapeu-
tic concentrations of octreotide to patients throughout
the interval between injections.
It is important to note the constraints of our study
that limit the interpretation of our findings. First, in
vivo rabbit PK data do not always accurately reflect, and
cannot replace, clinical PK studies in humans. A rabbit
PK profile similar to that of Sandostatin LAR is not
proof of clinical bioequivalence to Sandostatin LAR and
cannot replace demonstrating human bioequivalence.
This underlines the importance of performing clinical PK
studies in all new depot delivery systems of octreotide.
Second, clinical studies have to demonstrate equivalent
safety and efficacy in specific indications; target patient
populations include those with acromegaly or neuroen-
docrine tumors. In addition, although the in vivo study
described here was designed to evaluate the formulations
in an equal number of rabbits per cohort, needle clogging
in formulation B caused one animal to be excluded from
analysis and one animal to receive part of the intended
sample amount. Furthermore, only a small quantity of
formulation C was available and, therefore, this sample
could be evaluated only in three rabbits. A further study
with a larger sample size would strengthen the evidence
presented here. Finally, disparities in study design should
be taken into account: differences in serum sample time
points between formulations occurred because of
resource availability and the fact that the in vivo evalua-
tions of different formulations were performed on differ-
ent calendar dates. Nevertheless, it is reasonable to
compare the kinetic profile of the formulations because
the serum sample times covered the long in vivo release
profile expected in these products.
Sandostatin LAR consists of octreotide acetate encap-
sulated and uniformly distributed within PLGA D-(+)
glucose microspheres. Slow release of the drug occurs as
the polymer biodegrades, primarily through hydrolysis.
The polymer has an average molecular weight of ~52
kDa and the microparticles exhibit a mean diameter of
~50 μm [8].
Compared with the established characteristics of San-
dostatin LAR, formulations A and C exhibited greater
irregularity in microparticle shape and size. This is sug-
gestive of inadequately encapsulated octreotide mole-
cules and may indicate a lack of quality control in the
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microspheres and the thickness of the polymer coat in
formulations B and C have the potential to affect the
drug-release profile [9], with possible failure to deliver
continuous therapeutic drug concentrations, and/or can
potentially cause adverse events related to excessive
drug release during the initial burst phase. In addition,
differences in the mannitol appearance were observed
between the formulations. Since mannitol is used to
improve flow and dispersability and to improve stability
in drug delivery systems, it could be postulated that
changes in its appearance could affect the pharmaceuti-
cal processability of PLGA-based drug delivery systems
as well as the preparation of the drug for administration.
Factors such as the molecular weight and composition
of the PLGA polymer also affect drug release, with low
molecular weight accelerating the rate of drug release
and a high lactide:glycolide ratio causing the polymer to
d e g r a d em o r es l o w l yb e c a u s et h el a c t i d em o n o m e ri s
more hydrophobic than the glycolide monomer. In pre-
vious studies of octreotide release from PLGA polymers
of various molecular weights and lactide:glycolide ratios,
pH and impurity content also influenced the percentage
of octreotide release [10,11]. Although the very low
molecular weight in formulations A and C may be in
part offset by a higher amount of lactide monomer, the
differences in molecular weights and lactide:glycolide
ratios between the three formulations are likely to cause
different octreotide release patterns. As PLGA polymers
are routinely used in sustained-release formulations and
can be manufactured to a much higher purity than that
present in formulation B, the polymer can be considered
to be of poor quality. Variability was further evident in
the porosity of microparticles in formulations A and B.
Previous studies have found that biodegradation and
drug release are dependent on the porosity, with varia-
tions affecting the rate of drug mobility [12].
The high tin concentration found in formulation B
may indicate that high amounts of tin(II)-octoate were
used in the polymer synthesis without proper purifica-
tion, likely to be due to residual product from the cata-
lyst used during production of the polymer. As tin(II)-
octoate has been reported to be highly cytotoxic,[13]
this may affect patient safety. This impurity was not
observed in Sandostatin LAR or formulation A and no
arsenic content was found in any sample. Quality con-
trol to guarantee these characteristics is paramount to
LAR formulations. In addition, formulations A and B
had a low acid component to the octreotide salt. Theo-
retically, in the case of an acid-base pair, the ratio of
acetate molecules to octreotide molecules should be 2:1.
In these formulations, octreotide is likely to be present
as a free base rather than as an acetate salt indicating
that the other formulations do not share the same pro-
duct characteristics as Sandostatin LAR.
In conclusion, clear differences were seen between
Sandostatin LAR and formulations A, B and C, includ-
ing significant differences in the PK profile, and varia-
tions in microparticle size, shape molecular weight, acid:
base ratio, and impurity content. These findings suggest
that other long-acting octreotide formulations may have
a different drug-release pattern to that of Sandostatin
LAR despite similar composition. Considering these dif-
ferences, formulations A, B and C are most likely not
bioequivalent to Sandostatin LAR in humans. Conse-
quently, the safety and efficacy of these new formula-
tions cannot be inferred from the Sandostatin LAR
clinical and safety profile. Each of these other formula-
tions should be assessed by appropriate clinical studies
to determine their clinical benefit and safety profiles.
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